2020

21.01.2020 – SHL Telemedicine Ltd.

SHL Telemedicine confirms discussions regarding a possible merger or takeover transaction relating to the company

Press Release

SHL Telemedicine confirms discussions regarding a possible merger or takeover transaction relating to the company

Tel Aviv / Zurich, 21 January 2020 – Following an article published in the Israeli financial press this morning, SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it has been in discussions with a number of parties regarding a possible merger or takeover transaction relating to SHL. The parties include Danel Ltd., a public company listed at the Tel Aviv Stock Exhange. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to the realization of such transaction. SHL will further inform the market as required.

For further information, please contact:

Martin Meier-Pfister, IRF, phone +41 43 244 81 40, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call centre services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit the web site at www.shl-telemedicine.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.


close